Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $45.00.

A number of equities research analysts have issued reports on SLN shares. William Blair restated an "outperform" rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. The Goldman Sachs Group started coverage on shares of Silence Therapeutics in a research note on Tuesday, February 11th. They set a "sell" rating and a $6.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, January 29th. BMO Capital Markets restated an "outperform" rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Finally, Chardan Capital reiterated a "buy" rating and issued a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th.

Institutional Trading of Silence Therapeutics

A number of hedge funds have recently modified their holdings of SLN. Redmile Group LLC raised its position in shares of Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock worth $16,507,000 after purchasing an additional 500,000 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company's stock worth $19,798,000 after acquiring an additional 268,250 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after buying an additional 849,676 shares in the last quarter. Eventide Asset Management LLC purchased a new position in shares of Silence Therapeutics in the third quarter valued at $11,635,000. Finally, Point72 Asset Management L.P. grew its holdings in shares of Silence Therapeutics by 35.3% in the fourth quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company's stock valued at $4,356,000 after purchasing an additional 165,300 shares in the last quarter. Institutional investors own 98.73% of the company's stock.

Remove Ads

Silence Therapeutics Stock Performance

Shares of SLN traded down $0.22 during mid-day trading on Thursday, reaching $4.50. 177,021 shares of the company's stock traded hands, compared to its average volume of 324,562. Silence Therapeutics has a 12 month low of $4.06 and a 12 month high of $27.72. The stock has a market capitalization of $134.69 million, a P/E ratio of -2.87 and a beta of 1.05. The business's 50-day moving average price is $5.63 and its 200-day moving average price is $11.77.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.